Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Protein Degradation Specialist Gets $1bn Up Front

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Stand out from the crowd — Multiple SERDs are ahead of ARV-471 but Pfizer and Arvinas believe they have a best-in-class estrogen receptor degrader • Source: Alamy

Protein degradation specialist Arvinas, Inc. will receive $1bn up front and accelerate the development of its estrogen receptor protein degrader ARV-471, while Pfizer Inc. gets another opportunity to expand its already significant presence in breast cancer – with the blockbuster CDK4/6 inhibitor Ibrance (palbociclib) – under a deal announced on 22 July for the development and commercialization of Arvinas’ small molecule.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

15 Apr 2025

• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

Ironwood To Consider All Options With Apraglutide Setback In SBS

14 Apr 2025

• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

14 Apr 2025

• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.